Guardant Health, Inc.
GHHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeGuardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company carries a $20.67B market cap, placing it firmly in the large-cap category. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.
Market Cap
$20.67B
Beta
1.59
P/E (TTM)
—
P/E (Fwd)
-359.81
EPS (TTM)
$-3.41
EPS (Fwd)
$-0.43
ROE
—
ROA
-17.2%
Cash
$1.10B
Total Debt
$1.70B
Free CF
-$85.4M
52W Change
235.5%
Annual Financials
Cash vs Debt
On the balance sheet, GH has $1.10B in cash with $1.70B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$85.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $449.5M (2022) to $982.0M (2025), reflecting a 118% increase over the period.
A beta of 1.59 means GH is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Guardant Health, Inc.'s trajectory.